Research and Clinical Trials

We are dedicated to offering you the latest and most innovative cancer care. Our doctors and research team will match you to the trial that is right for you. They will also discuss the risks and benefits of participating in a particular trial. We collaborate with Dayton Clinical Oncology Program as well as offering the following trials to bring research right here… close to home.

We are currently enrolling for the following trials:

Prostate Cancer Trials :

Novartis Lutetium Vipivotide Tetraxetan (CAAA617D12302) -  NCT05939414
An International, Prospective, Open-label, Multi-center, Randomized Phase III Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) Versus Observation to Delay Castration or Disease Recurrence in Adult Male Patients With Prostate-specific Membrane Antigen (PSMA) Positive Oligometastatic Prostate Cancer (OMPC)

Curium Solar - NCT06235151 
A Phase 3, Multicenter, Open-label Study to Test the Diagnostic Performance of Copper Cu 64 PSMA I&T PET/CT in Staging of Men with Newly Diagnosed Unfavorable Intermediate-risk, High risk or Very High-risk Prostate Cancer Electing to Undergo Radical Prostatectomy with Pelvic Lymph Node Dissection.

Mdxhealth GPS Pro-CDI Trial - NCT# N/A
Impact of the Genomic Prostate Score on shared decision-making of patients with VLR, LR, FIR, UFIR, and HR prostate cancer.

Bladder Cancer Trials:

J&J MoonRISe-3 - NCT06919965
A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants With High-risk Non-muscle-invasive Bladder Cancer With Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG)

General Urology Trials:

Opening Soon CREDIBLE - NCT06394869
Cystoscopic REDuction In BLadder Evaluations for Microhematuria - A Prospective Randomized, Controlled, Clinical Utility Study for Evaluation of Microhematuria (The CREDIBLE Study)

Breast Cancer Trials:

Olema Opera-01 OP-1250-301 - NCT06016738
A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (OPERA-01)

Opening Soon BeOne BGB-43395-302 – NCT# Coming Soon
An Open-Label, Randomized, Multicenter Phase 3 Study Investigating the Efficacy and Safety of BGB-43395 Plus Letrozole versus CDK4/6 Inhibitors (Abemaciclib, Palbociclib, Ribociclib) Plus Letrozole in Patients with Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Systemic Anticancer Treatment for Advanced or Metastatic Disease

CLL/SLL Trials:
BeOne BGB-16673-302 - NCT06846671
A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both BTK and BCL2 Inhibitors

BeOne BGB-16673-304 - NCT06973187
A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Lung Cancer Trials:

Opening Soon BioNTech BNT 327 - NCT06712316
A Phase II/III, Multisite, Randomized Master Protocol for a Global Trial of BNT327 in Combination With Chemotherapy and Other Investigational Agents in First-line Non-small Cell Lung Cancer

General Hematology/Oncology Trials:

Opening Soon Natera Bespoke Pan Cancer- Natera Protocol # 25-092-NCP
A prospective, multi-center, single arm study designed to collect data to clinically characterize biomarkers associated with Natera test(s) from participants diagnosed with Stage I to IV tumors, for whom standard of care Natera MRD testing has been ordered (such as SignateraTM, SignateraTM Genome, or LatitudeTM). Data collection will occur annually for up to five (5) years.